- J&J’s Ad26 vector-based vaccine demonstrated robust immune response in the pre-clinical study by neutralizing Abs, preventing infection and provide complete/ near-complete protection in the lungs from the virus in NHPs
- Based on the preclinical studies, the company has commenced the P-I/IIa study of Ad26.COV2.S, in healthy volunteers in the US and Belgium with expected initiation of P-III study in Sept’2020. The P-I/IIa study will evaluate the safety, reactogenicity, and immunogenicity of Ad26.COV2.S in ~1,000 healthy adults aged 18-55yrs. and 65+ yrs.
- Additionally, the company is planning to initiate P-III clinical trial program, will evaluate both one/two-dose regimens of Ad26.COV2.S initiate in parallel studies while the P-IIa study in the Netherlands, Spain, and Germany and a P-I study in Japan in underway
Click here to read full press release/ article | Ref: Johnson & Johnson | Image: StraitTimes